HC Wainwright began coverage on shares of Evaxion Biotech A/S (NASDAQ:EVAX – Free Report) in a report published on Monday, MarketBeat reports. The brokerage issued a buy rating and a $14.00 price target on the stock. HC Wainwright also issued estimates for Evaxion Biotech A/S’s FY2023 earnings at ($6.90) EPS, FY2024 earnings at ($0.10) EPS, […]
Related Keywords
, Jpmorgan Chase Co , Beacon Capital Management , Elm Advisors , Ae Wealth Management , Susquehanna International Group , Evaxion Biotech , Free Report , Get Free Report , International Group , Capital Management , Evaxion Biotecha S , Nasdaq Evax , Devax , Medical , Initiated Coverage , Hc Wainwright ,
vimarsana.com © 2020. All Rights Reserved.